22 research outputs found
Recommended from our members
CD4+ Count–Guided Interruption of Antiretroviral Treatment
BACKGROUND
Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV).
Full Text of Background...
METHODS
We randomly assigned persons infected with HIV who had a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy (the viral suppression group) or the episodic use of antiretroviral therapy (the drug conservation group). Episodic use involved the deferral of therapy until the CD4+ count decreased to less than 250 per cubic millimeter and then the use of therapy until the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease.
RESULTS
A total of 5472 participants (2720 assigned to drug conservation and 2752 to viral suppression) were followed for an average of 16 months before the protocol was modified for the drug conservation group. At baseline, the median and nadir CD4+ counts were 597 per cubic millimeter and 250 per cubic millimeter, respectively, and 71.7% of participants had plasma HIV RNA levels of 400 copies or less per milliliter. Opportunistic disease or death from any cause occurred in 120 participants (3.3 events per 100 person-years) in the drug conservation group and 47 participants (1.3 per 100 person-years) in the viral suppression group (hazard ratio for the drug conservation group vs. the viral suppression group, 2.6; 95% confidence interval [CI], 1.9 to 3.7; P<0.001). Hazard ratios for death from any cause and for major cardiovascular, renal, and hepatic disease were 1.8 (95% CI, 1.2 to 2.9; P=0.007) and 1.7 (95% CI, 1.1 to 2.5; P=0.009), respectively. Adjustment for the latest CD4+ count and HIV RNA level (as time-updated covariates) reduced the hazard ratio for the primary end point from 2.6 to 1.5 (95% CI, 1.0 to 2.1).
CONCLUSIONS
Episodic antiretroviral therapy guided by the CD4+ count, as used in our study, significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antiretroviral therapy, largely as a consequence of lowering the CD4+ cell count and increasing the viral load. Episodic antiretroviral therapy does not reduce the risk of adverse events that have been associated with antiretroviral therapy. (ClinicalTrials.gov number, NCT00027352.
Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
ArtÃculo de publicación ISIObjectives
The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have
not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a
randomized international clinical trial that compares immediate with deferred initiation of ART
for HIV-positive individuals with CD4 cell counts above 500 cells/μL. We describe the
demographics, HIV-specific characteristics and medical history of this cohort.
Methods
Data collected at baseline include demographics, HIV-specific laboratory values, prior medical
diagnoses and concomitant medications. Baseline characteristics were compared by geographical
region, gender and age.
Results
START enrolled 4685 HIV-positive participants from 215 sites in 35 countries. The median age is
36 years [interquartile range (IQR) 29–44 years], 27% are female, and 45% self-identify as white,
30% as black, 14% as Latino/Hispanic, 8% as Asian and 3% as other. The route of HIV
acquisition is reported as men who have sex with men in 55% of participants, heterosexual sex
in 38%, injecting drug use in 1% and other/unknown in 5%. Median time since HIV diagnosis is
1.0 year (IQR 0.4–3.0 years) and the median CD4 cell count and HIV RNA values at study entry
are 651 cells/μL (IQR 584–765 cells/μL) and 12 754 HIV RNA copies/mL (IQR 3014–43 607
copies/mL), respectively.
Conclusions
START has enrolled a diverse group of ART-naïve individuals with high CD4 cell counts who are
comparable to the HIV-positive population from the regions in which they were enrolled. The
information collected with this robust study design will provide a database with which to
evaluate the risks and benefits of early ART use for many important outcomes